ZVS204e

ZVS204e is a novel small molecule therapeutic candidate developed by Virtuoso Therapeutics. It is designed as a potent and selective inhibitor of the Janus kinase 2 (JAK2) signaling pathway, specifically targeting the JAK2 V617F mutation which is a primary driver in various myeloproliferative neoplasms (MPNs). By inhibiting the constitutively active JAK2 protein, ZVS204e aims to reduce the uncontrolled proliferation of hematopoietic cells and alleviate symptoms associated with conditions such as polycythemia vera, essential thrombocythemia, and myelofibrosis. The compound is engineered to provide improved selectivity over other JAK family members (JAK1, JAK3, and TYK2) to potentially minimize off-target toxicities like anemia and thrombocytopenia often seen with non-selective JAK inhibitors.